fda glp-1 warning letters september 2025 news FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

28.78

★★★★☆4.8 (126)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

29.17

★★★★★4.9 (98)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

24.75

★★★★★5.0 (157)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

24.47

★★★★★4.7 (84)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

20.27

★★★★★4.9 (203)

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the sale of

25.19

★★★★★5.0 (176)

September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

27.46

★★★★★4.8 (132)